Oragenics, Inc. Receives Further Validation for Lantibiotic Compound OG716 (Business Insurance)

Oragenics, Inc. Receives Further Validation for Lantibiotic Compound OG716

UF startup Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), announced the publication of a preclinical study using the lead compound from its lantibiotics program, OG716, in the peer-reviewed journal, Antimicrobial Agents and Chemotherapy. Oragenics is an alumnus of UF Innovate | Sid Martin Biotech.

The preclinical study demonstrated that following oral administration of the maximum feasible dose of OG716 in hamster models, there were no observable toxicities nor observable side effects, nor was there any effect on intestinal motility. Treatment of animals infected with C. difficile resulted in a dose-dependent survival, and no recurrence at the upper dose tested. Further, researchers observed that the compound remained constrained only in the gastrointestinal tract. Lantibiotics, including OG716, are a novel class of peptide antibacterial compounds naturally produced by a variety of Gram-positive bacteria. Oragenics’ lantibiotic library offers a large pipeline for the development of novel antibiotics in several indications.

Learn more about Oragenics, Inc. Receives Further Validation for Lantibiotic Compound OG716.
X